MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412980 | Name: Cizolirtine (free base)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cizolirtine (free base) is an analgesic with no ulcerogenic effects.

Chemical Structure

Cizolirtine (free base)
Cizolirtine (free base)
CAS#142155-43-9 (free base)

Theoretical Analysis

MedKoo Cat#: 412980

Name: Cizolirtine (free base)

CAS#: 142155-43-9 (free base)

Chemical Formula: C15H21N3O

Exact Mass: 259.1685

Molecular Weight: 259.35

Elemental Analysis: C, 69.47; H, 8.16; N, 16.20; O, 6.17

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
142155-43-9 (free base) 251375-82-3 (citrate)
Synonym
Cizolirtine (free base); UNII-SMP167WV5D
IUPAC/Chemical Name
N,N-dimethyl-2-((1-methyl-1H-pyrazol-5-yl)(phenyl)methoxy)ethan-1-amine
InChi Key
DCMJBKFKXGPPMT-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H21N3O/c1-17(2)11-12-19-15(13-7-5-4-6-8-13)14-9-10-16-18(14)3/h4-10,15H,11-12H2,1-3H3
SMILES Code
CN(CCOC(c1n(C)ncc1)c2ccccc2)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 259.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Monck N. Cizolirtine. Laboratorios Dr Esteve. Curr Opin Investig Drugs. 2001 Sep;2(9):1269-72. PMID: 11717814. 2: Zát'ura F, Vsetica J, Abadías M, Pavlík I, Schraml P, Brod'ák M, Villoria J, Sust M; E-4018/CL50 Study Group. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof- of-concept study. Eur Urol. 2010 Jan;57(1):145-52. doi: 10.1016/j.eururo.2009.04.045. Epub 2009 May 7. PMID: 19446951. 3: Martínez-García R, Abadías M, Arañó P, Perales L, Ruíz JL, Sust M, Conejero J; ESCLIN 006/00 study group. Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study. Eur Urol. 2009 Jul;56(1):184-90. doi: 10.1016/j.eururo.2008.04.027. Epub 2008 Apr 18. PMID: 18485575. 4: Fernández de Henestrosa A, Marín AP, Tortajada A, Vila C, Guzmán A. Assessment of the Genotoxic Potential of Cizolirtine a Substance-P and Calcitonin Gene-Related Peptide Release Modulator. Drug Res (Stuttg). 2020 Nov 4. doi: 10.1055/a-1286-5358. Epub ahead of print. PMID: 33147634. 5: Aubel B, Kayser V, Mauborgne A, Farré A, Hamon M, Bourgoin S. Antihyperalgesic effects of cizolirtine in diabetic rats: behavioral and biochemical studies. Pain. 2004 Jul;110(1-2):22-32. doi: 10.1016/j.pain.2004.03.001. PMID: 15275748. 6: Aubel B, Kayser V, Farré A, Hamon M, Bourgoin S. Evidence for adenosine- and serotonin-mediated antihyperalgesic effects of cizolirtine in rats suffering from diabetic neuropathy. Neuropharmacology. 2007 Feb;52(2):487-96. doi: 10.1016/j.neuropharm.2006.08.017. Epub 2006 Oct 5. PMID: 17027046. 7: Pavlik I, Suchy J, Pacík D, Bokr R, Sust M, Villoria J, Abadías M; Evaluation of Cizolirtine Citrate to Treat Renal Colic Pain Study Group. Comparison of cizolirtine citrate and metamizol sodium in the treatment of adult acute renal colic: a randomized, double-blind, clinical pilot study. Clin Ther. 2004 Jul;26(7):1061-72. doi: 10.1016/s0149-2918(04)90178-6. PMID: 15336471. 8: Shembalkar P, Täubel J, Abadias M, Arezina R, Hammond K, Anand P. Cizolirtine citrate (E-4018) in the treatment of chronic neuropathic pain. Curr Med Res Opin. 2001;17(4):262-6. PMID: 11922399. 9: Ballet S, Aubel B, Mauborgne A, Poliénor H, Farré A, Cesselin F, Hamon M, Bourgoin AS. The novel analgesic, cizolirtine, inhibits the spinal release of substance P and CGRP in rats. Neuropharmacology. 2001 Mar;40(4):578-89. doi: 10.1016/s0028-3908(00)00186-6. PMID: 11249967. 10: Sawynok J. Methylxanthines and pain. Handb Exp Pharmacol. 2011;(200):311-29. doi: 10.1007/978-3-642-13443-2_11. PMID: 20859801.